- Home
- APP vs ABBV Comparison
APP vs ABBV Comparison
Compare APP & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APP | ABBV |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.9B | 358.5B |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | APP | ABBV |
|---|---|---|
| Price | $468.61 | $234.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 18 |
| Target Price | ★ $694.44 | $253.71 |
| AVG Volume (30 Days) | ★ 5.4M | 3.8M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | ★ 115.23 | N/A |
| EPS | ★ 3.56 | 0.39 |
| Revenue | $5,480,717,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $47.88 | $11.87 |
| Revenue Next Year | $29.14 | $8.12 |
| P/E Ratio | ★ $132.02 | $590.00 |
| Revenue Growth | ★ 16.38 | 8.57 |
| 52 Week Low | $325.69 | $181.75 |
| 52 Week High | $745.61 | $244.81 |
Technical Indicators
Market Signals| Indicator | APP | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 40.92 | 65.14 |
| Support Level | $362.60 | $220.11 |
| Resistance Level | $499.42 | $242.05 |
| Average True Range (ATR) | 31.30 | 5.34 |
| MACD | -11.49 | 0.39 |
| Stochastic Oscillator | 13.18 | 95.34 |
Price Performance
Historical ComparisonAbout APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.